FDA assigns priority review to supplemental New Drug Application for lorlatinib as a first-line treatment for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

Submission for this 3rd-generation ALK inhibitor (AI) developed to inhibit tumour mutations that drive resistance to other AIs and to penetrate blood brain barrier is supported by data from CROWN study which met primary endpoint of improved progression-free survival vs.crizotinib

Source:

Biospace Inc.